Search

Jasper H Yik

from Elk Grove, CA
Age ~53
Get Report
Also known as:
Jasper Hoinel Yik, I Yik, L Yik Jasper
Related to:
Kimberly K Jackson, 57Sharon Kirkpatrick, 74Nicole Kirkpatrick, 41Kimberly Ransome, 57Kimberly S Kirkpatrick, 46Karl E Kirkpatrick, 48
Connected to:
Cheung Yik, 54Chong Yik, 95Yuen C Yik, 70Ayla Yildirim, 45Bekir H Yildirim, 67Betul O Yildirim, 42Bora A Yildirim, 36Emine Yildirim, 33Haluk Yildirim, 53Nihat Yildirim, 71

Jasper Yik Phones & Addresses

  • Elk Grove, CA
  • 1627 University Ave, Berkeley, CA 94703 (510) 549-0711
  • 568 Vistamont Ave, Berkeley, CA 94708 (510) 527-8194
  • Edmond, OK
  • Oklahoma City, OK
  • 734 Bush St, San Francisco, CA 94108 (415) 956-2842
  • 10182 Patti Way, Elk Grove, CA 95757

Work

Company: Uc davis medical center Position: Project scientist at uc davis medical center

Education

Degree: High school graduate or higher

Industries

Hospital & Health Care

Resumes

Resumes

Jasper Yik Photo 1

Project Scientist At Uc Davis Medical Center

View page
Location:
Elk Grove, CA
Industry:
Hospital & Health Care
Work:
Uc Davis Medical Center
Project Scientist at Uc Davis Medical Center

Publications

Us Patents

Heximi As A Suppressor Of Hiv Replication And Cardiac Hypertrophy

View page
US Patent:
20070020239, Jan 25, 2007
Filed:
Sep 25, 2006
Appl. No.:
11/526452
Inventors:
Qiang Zhou - Berkeley CA, US
Jasper Yik - Berkeley CA, US
Ruichuan Chen - Berkeley CA, US
International Classification:
A61K 48/00
A61K 31/44
A61K 31/295
A61K 31/195
A61K 31/19
US Classification:
424093200, 514044000, 514357000, 514575000, 514563000, 514501000
Abstract:
Cellular transcription is modulated by increasing or decreasing the amount of active HEXIM1 in the cell. The methods are applied to the treatment of HIV infection and cardiac hypertrophy. Assays using reconstituted 7SK:P-TEFb snRNP screen for agents that modulate HEXIM1-P-TEFb binding.

Cartilage Oligomeric Matrix Protein (Comp)-Growth Factor Complexes And Uses Thereof

View page
US Patent:
20130315889, Nov 28, 2013
Filed:
Sep 14, 2011
Appl. No.:
13/879399
Inventors:
Dominik Haudenschild - Davis CA, US
Paul Di Cesare - Sacramento CA, US
Jasper Yik - Elk Grove CA, US
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
C07K 14/78
C07K 14/495
C07K 14/51
C07K 14/485
US Classification:
424 944, 530399, 514 76, 514 93, 514 89, 514 88, 435375, 435377
Abstract:
The present invention relates to protein complexes or scaffold comprising cartilage oligomeric matrix protein (COMP) polypeptides bound to one or more growth factors, and methods of their use in promoting chondrogenesis and/or osteogenesis, and repair of cartilage and bone lesions.

Hexim1 As A Suppressor Of Hiv Replication And Cardiac Hypertrophy

View page
US Patent:
20060047004, Mar 2, 2006
Filed:
Aug 27, 2004
Appl. No.:
10/928009
Inventors:
Qiang Zhou - Berkeley CA, US
Jasper Yik - Berkeley CA, US
Ruichuan Chen - Berkeley CA, US
International Classification:
A61K 31/225
A61K 31/19
A61K 31/16
US Classification:
514575000, 514547000, 514616000
Abstract:
Cellular transcription is modulated by increasing or decreasing the amount of active HEXIM1 in the cell. The methods are applied to the treatment of HIV infection and cardiac hypertrophy. Assays using reconstituted 7SK:P-TEFb snRNP screen for agents that modulate HEXIM1-P-TEFb binding.

Use Of Cdk9 Inhibitors To Reduce Cartilage Degradation

View page
US Patent:
20230109457, Apr 6, 2023
Filed:
May 9, 2022
Appl. No.:
17/739401
Inventors:
- Oakland CA, US
Paul Di Cesare - Sacramento CA, US
Jasper Yik - Elk Grove CA, US
Blaine Christiansen - Woodland CA, US
International Classification:
A61K 31/453
A61K 31/713
A01N 1/02
A61K 9/00
Abstract:
The present invention relates to the use of cyclin-dependent kinase 9 (CDK9) inhibitors to reduce, inhibit and/or prevent cartilage degradation. CDK9 inhibitors can be used to reduce, inhibit and/or prevent cartilage degradation and loss of cartilage viability during allograft storage. CDK9 inhibitors can be used as a post-injury intervention treatment to reduce, inhibit and/or prevent the acute cellular responses that lead to future cartilage degradation and osteoarthritis.

Use Of Cdk9 Inhibitors To Reduce Cartilage Degradation

View page
US Patent:
20210008054, Jan 14, 2021
Filed:
Apr 30, 2020
Appl. No.:
16/863892
Inventors:
- Oakland CA, US
Paul DI CESARE - Sacramento CA, US
Jasper YIK - Elk Grove CA, US
Blaine CHRISTIANSEN - Woodland CA, US
Assignee:
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA - Oakland CA
International Classification:
A61K 31/453
A61K 31/713
A01N 1/02
A61K 9/00
Abstract:
The present invention relates to the use of cyclin-dependent kinase 9 (CDK9) inhibitors to reduce, inhibit and/or prevent cartilage degradation. CDK9 inhibitors can be used to reduce, inhibit and/or prevent cartilage degradation and loss of cartilage viability during allograft storage. CDK9 inhibitors can be used as a post-injury intervention treatment to reduce, inhibit and/or prevent the acute cellular responses that lead to future cartilage degradation and osteoarthritis.

Use Of Cdk9 And Brd4 Inhibitors To Inhibit Inflammation

View page
US Patent:
20200046726, Feb 13, 2020
Filed:
May 23, 2019
Appl. No.:
16/421218
Inventors:
- Oakland CA, US
Jasper YIK - Elk Grove CA, US
International Classification:
A61K 31/5513
A61K 45/06
A61K 31/352
A61K 31/551
A61K 31/445
Abstract:
Provided are methods for the combined use of cyclin-dependent kinase 9 (CDK9) inhibitors and bromodomain containing 4 (BRD4) inhibitors to reduce, inhibit and/or prevent cartilage degradation and systemic traumatic inflammation. A combination of CDK9 inhibitors and BRD4 inhibitors can be used to reduce, inhibit and/or prevent cartilage degradation and loss of cartilage viability during allograft storage. A combination of CDK9 inhibitors and BRD4 inhibitors can be used as a post-injury intervention treatment to reduce, inhibit and/or prevent the acute cellular responses that lead to future cartilage degradation and osteoarthritis.

Use Of Cdk9 Inhibitors To Reduce Cartilage Degradation

View page
US Patent:
20190255034, Aug 22, 2019
Filed:
Nov 20, 2018
Appl. No.:
16/196955
Inventors:
- Oakland CA, US
Paul Di CESARE - Sacramento CA, US
Jasper YIK - Elk Grove CA, US
Blaine CHRISTIANSEN - Woodland CA, US
Assignee:
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA - Oakland CA
International Classification:
A61K 31/453
A61K 9/00
A61K 31/713
A01N 1/02
Abstract:
The present invention relates to the use of cyclin-dependent kinase 9 (CDK9) inhibitors to reduce, inhibit and/or prevent cartilage degradation. CDK9 inhibitors can be used to reduce, inhibit and/or prevent cartilage degradation and loss of cartilage viability during allograft storage. CDK9 inhibitors can be used as a post-injury intervention treatment to reduce, inhibit and/or prevent the acute cellular responses that lead to future cartilage degradation and osteoarthritis.

Use Of Cdk9 And Brd4 Inhibitors To Inhibit Inflammation

View page
US Patent:
20170304315, Oct 26, 2017
Filed:
Oct 13, 2015
Appl. No.:
15/517476
Inventors:
- Oakland CA, US
Jasper YIK - Elk Grove CA, US
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
A61K 31/5513
A61K 31/352
A61K 45/06
A61K 31/445
A61K 31/00
Abstract:
Provided are methods for the combined use of cyclin-dependent kinase 9 (CDK9) inhibitors and bromodomain containing 4 (BRD4) inhibitors to reduce, inhibit and/or prevent cartilage degradation and systemic traumatic inflammation. A combination of CDK9 inhibitors and BRD4 inhibitors can be used to reduce, inhibit and/or prevent cartilage degradation and loss of cartilage viability during allograft storage. A combination of CDK9 inhibitors and BRD4 inhibitors can be used as a post-injury intervention treatment to reduce, inhibit and/or prevent the acute cellular responses that lead to future cartilage degradation and osteoarthritis.
Control profile
Jasper H Yik from Elk Grove, CA, age ~53 Get Report